

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number  
**WO 03/035092 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 35/78,**  
47/00

Apt. 111-801, Jeonmin-dong, Yousung-gu, 305-727 Daejeon (KR).

(21) International Application Number: PCT/KR02/02000

(72) Inventors; and

(22) International Filing Date: 25 October 2002 (25.10.2002)

(75) Inventors/Applicants (for US only): **PARK, Byung-Young** [KR/KR]; Parangsae Apt.104-902, Dunsan-dong, Seo-gu, 302-120 Daejeon (KR). **MOON, Chang-Hee** [KR/KR]; Boram villa B-104, 108-57, Doma2-dong, Seo-gu, 302-162 Daejeon (KR). **PARK, Eun-Kyu** [KR/KR]; 45-7, Domal-dong, Seo-gu, 302-161 Daejeon (KR). **KIM, Kyoung-Mi** [KR/KR]; LG dong-a Apt. 105-302, Hosung-dong, Dukjin-gu, 561-210 Cheonju (KR).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2001/66246 26 October 2001 (26.10.2001) KR  
2002/63407 17 October 2002 (17.10.2002) KR

(74) Agent: **SHIN, Dong-In**; D.I. International Patent Office, #304, Dukam Bldg., 1457-2, Seocho3-dong, Seocho-gu, 137-867 Seoul (KR).

(71) Applicant (for all designated States except US): **ANGIOLAB INC.** [KR/KR]; 439-6 Doma2-dong, Seo-gu, 302-735 Daejeon (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,

(71) Applicant and

(72) Inventor: **KIM, Min-Young** [KR/KR]; Samsung Pureun

[Continued on next page]

(54) Title: COMPOSITION CONTAINING HORSE CHESTNUT EXTRACT FOR ANTI-ANGIOGENIC AND MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY



(57) Abstract: The present invention relates to a composition containing Horse chestnut extract that inhibits angiogenesis and matrix metalloproteinase activity. The Horse chestnut extract of the present invention inhibits angiogenesis and activity of matrix metalloproteinase, so that it can be applied to treat disease related to angiogenesis and matrix metalloproteinase.

WO 03/035092 A1



LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# COMPOSITION CONTAINING HORSE CHESTNUT EXTRACT FOR ANTI-ANGIOGENIC AND MATRIX METALLOPROTEINASE INHIBITORY ACTIVITY

## 5 FIELD OF INVENTION

The present invention relates to a composition comprising Horse chestnut extract having anti-angiogenic and matrix metalloproteinase inhibitory activity for the prevention and treatment of diseases caused by abnormal angiogenesis and its use thereof.

10

## BACKGROUND OF THE INVENTION

Angiogenesis is the process of generating new capillary blood vessels. Neovascularization is tightly regulated, and activation occurs in embryogenic development, tissue remodeling, wound healing and periodic cycles of corpus luteum  
15 development (Folkman and Cotran; *Int. Rev. Exp. Pathol.*, 16, pp207-248, 1976).

Vasculogenesis means the formation of new endothelial cell during the embryogenesis in order to supply the nutrient for rapidly growing fetus. On the contrary, capillary blood vessel endothelial cells are started to proliferate from  
20 existing vasculature in angiogenesis. The endothelial cells are growing very slowly as compared with other types of cells in the body. However, the proliferation of these cells is induced by pro-angiogenic cytokines, inflammation mediators and activated proteolytic enzymes.

By the failure of regulation of angiogenesis, some pathological syndromes are  
25 developed (Timar; *J. Pathol. Oncol. Res.*, 6, pp85-94, 2001). Pathological angiogenesis is involved in many diseases. For example, cardiovascular diseases such as angioma, angiofibroma, vascular deformity, atherosclerosis, synechia and edemic

sclerosis; and ophthalmological diseases such as neovascularization after cornea implantation, neovascular glaucoma, diabetic retinopathy, angiogenic corneal disease, macular degeneration, pterygium, retinal degeneration, retrolental fibroplasias, and granular conjunctivitis are diseases related to angiogenesis. Chronic inflammatory diseases such as arthritis; dermatological disease such as psoriasis, telangiectasis, pyogenic granuloma, seborrheic dermatitis and acne are also angiogenesis-dependent diseases.

In particular, angiogenesis is essential to metastasis and growth of cancer (D'Amato RJ and Adamis AP, *Ophthalmol.*, 102, pp1261-1262, 1995; Arbiser JL, *J. Am. Acad. Derm.*, 34, pp486-497, 1996; O'Brien K.D. *et al.*; *Circulation*, 93, pp672-682, 1996; Hanahan D and Folkman J, *Cell*, 86, pp353-364, 1996). New blood vessels not only provide nutrients and oxygen to fast-growing cancer cells, but also give ways of entering to the blood stream resulting metastasis (Polverini P.J., *Critical Reviews in Oral Biology*, 6, pp230-247, 1995). Currently, a large variety of chemotherapies and immunotherapies are applied in the treatment of cancer, but the efficacy of the therapies is limited and nothing can successfully extend the life of cancer patients due to the lack of anti-metastasis effects.

Arthritis, a well-known inflammatory disease, is initiated as an autoimmune disease. As the progression of the inflammation, the growth of vascular endothelial cell in the synovial cavity is activated by the cytokines. The cartilage in the articulation is finally destroyed by the formation of articular lamina leak (Kocb AE, *et al.*, *Arth. Rheum.*, 29, pp471-479, 1986; Stupack DG, *et al.*; *Braz. J. Med. Biol. Rcs.*, 32, pp578-581, 1999; Koch AE; *Arthritis Rheum.*, 41, pp951-962, 1998).

Many people are losing their eyesight all over the world because of various ocular diseases. Many patients became blindness due to the infiltration of the capillary blood cells into the vitreous humor (Jeffrey MI and Takayuki A, *J. Clin. Invest.*, 103, pp1231-1236, 1999). Therefore, inhibition of angiogenesis is the basic therapeutic

modality for these diseases.

Psoriasis is caused by extremely active proliferation of skin cells. Fast-growing cells requires sufficient blood supply, and angiogenesis is abnormally induced in psoriasis (Folkman J., *J. Invest. Dermatol.*, 59, pp40-48, 1972).

5        Since angiogenesis is closely related to initiation and progression of many diseases, many efforts have been made toward the development of angiogenesis inhibitors in order to prevent and/or treat those diseases.

Not only reorganization of the blood vessel by migration, proliferation and differentiation of endothelial cells, but also degradation of the extracellular matrix is required for angiogenesis. One of the major events for inducing angiogenesis is a breakdown of the extracellular matrix before the formation of the capillary blood vessels. The most important enzyme of matrix degradation is matrix metalloproteinase (MMP), a family of over 20 proteins. MMPs are endopeptidase, which degrade or proteolyze the components of the extracellular matrix such as collagen, proteoglycan, and gelatin, and are classified into four groups: collagenase, gelatinase, stromelysin, and membrane-type MMP. Many enzymes in the MMP family have substrate specificity. The expression of MMP is induced under various physiological circumstances when remodeling of an extracellular matrix is required (Curry TE Jr., Osteen KG; *Biol. Repord.*, 64, pp1285-1296, 2001; Damjanovske S, *et al.*, *Ann. NY Acad. Sci.*, 926, pp180-191, 2000; Ravanti L, Kahari VM, *Int. J. Mol. Med.*; 6, pp391-407, 2000).

Increased expression or activation of MMPs is observed in many pathological states, such as atherosclerosis, restenosis, MMP-dependent-osteopathy, inflammation of the central nervous system, Alzheimer's disease, skin aging, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal ulcer, synechia, bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss, myelinated nerve loss, liver fibrosis, nephroglomerular disease, germinal membrane ruptures, inflammatory bowel

disease, gingivitis, periodontitis, senile macular degeneration, diabetic retinopathy, proliferate vitreous body retinopathy, immature retinopathy, eye inflammation, conical cornea, Sjogren's syndrome, myopia, eyes tumors, rejection of cornea implantation, angiogenesis and cancer metastasis. (Woessner Jr., *Ann. NY. Acad. Sci.*, 732, pp11-21, 1994; Warner *et al.*, *Am. J. Pathol.*, 158, pp2139-44, 2001; Stetler-Stevenson, *Surg. Oncol. Clin. N. Am.*, 10, pp383-92, 2001).

For example, stromelysins are known to be the major enzyme for disruption of cartilage (Murphy, G. *et al.*, *Biochem. J.*, 248, pp265-268, 1987). Collagenases, gelatinases and stromelysins are responsible for the degradation of the extracellular matrix in many retinopathies (Bruns, F.R. *et al.*, *Invest. Ophthalmol. and Visual Sci.*, 32, pp1569-1575, 1989). Collagenases and stromelysins are identified in fibroblast from gingiva in inflammation, and the activity of the enzyme is dependent on the degree of inflammation (Overall, C.M. *et al.*, *J Periodontal Res*, 22, pp81-88, 1987). MMP activity is highly enhanced in response to the bacterial infection and inflammation in gingival crevicular fluid taken from patients with periodontal disease. Destruction of collagen, a major structural component of the periodontal matrix, by MMP leads to gingival recession, pocket formation and tooth movement (Goulb, L.B., Ryan M.E. Williams R.C., *Dent. Today*, 17, pp102-109).

Recent reports have also shown that MMP-1 activity is highly induced in Alzheimer's disease, and MMP-1 and MMP-3 are involved in the pathophysiology of the disease (Leake A, *et al.*; *J. Neurosci. Lett.*, 291, pp201-3, 2000; Yoshiyama Y, *et al.*, *Acta Neuropathol. (Berl)*, 99, pp91-5, 2000).

MMPs are also responsible in solar UV radiation-induced skin damage, affecting skin tone and resiliency leading to premature aging. The symptom of that include leathery texture, wrinkles, mottled pigmentation, laxity and sallowness. Therefore, MMP inhibitors could be included in cosmetics for anti-photoaging or anti-wrinkle treatment (Hase T, *et al.*, *Br. J. Dermatol.*, 142, pp267-273, 2000; Fisher G.J,

*et al.*; *Photochem. Photobiol.*, 69, pp154-157, 1999).

Since inhibitors for MMP and angiogenesis can be applied to the treatment and prevention of many diseases, development of angiogenesis inhibitor as new therapeutics is expected. Since these inhibitors need to be administered for a long time,  
5 desirable inhibitors should not have toxic or adverse effect with good patient compliance.

Horse chestnut is a plant in Hippocastanaceae, cultivated in many countries in Europe and Asia. Triterpene saponin mixture known as aescin (also called as escin) consists of diacylated tetra- and pentahydroxy-beta-amyrin compounds is a chief  
10 component of the seeds. Various flavonoids and polysaccharides are also included in the seeds. In addition to aescin, the leaves contain hydroxycoumarin such as esculin, fraxin and scopolin and flavonoids including rutin, quercitrin and isoquercitrin.

In folk medicine, the leaves have been used as a cough remedy. Japanese Horse chestnut seeds are given to patient with gastric pain, malaria, and diarrhea.  
15 Purified extract from Horse chestnut seed can be used for preparation of traditional Japanese cakes.

Horse chestnut seeds are used for treatment of symptoms in chronic venous insufficiency, because of anti-exudative and vascular tightening effects of the principal ingredient of seed extract, aescin.

20

The present inventors have endeavored to study the inhibitory effect of Horse chestnut extract on angiogenesis and matrix metalloproteinase and have finally found that the Horse chestnut extract could be used to inhibit angiogenesis- and MMP-dependent diseases.

25

DISCLOSURE OF THE INVENTION

Accordingly, it is an object of the present invention to provide an anti-  
5 angiogenic composition comprising Horse chestnut extract for inhibiting angiogenesis.

It is another object of the present invention to provide a pharmaceutical composition comprising a Horse chestnut extract as an active ingredient for prevention and treatment of angiogenesis – dependent diseases.

It is another object of the present invention to provide a composition to inhibit  
10 matrix metalloproteinase activity comprising the Horse chestnut extract as an active ingredient.

Also, it is another object of the present invention to provide a pharmaceutical composition comprising a Horse chestnut extract as an active ingredient for prevention and treatment of matrix metalloproteinase - dependent diseases.

15 It is another object of the present invention to provide a use of a Horse chestnut extract for the preparation of a pharmaceutical composition for inhibit and treat angiogenesis-dependent diseases.

It is another object of the present invention to provide a use of the Horse chestnut extract for preparation of pharmaceutical composition to inhibit MMP  
20 activity.

It is another object of the present invention to provide a pharmaceutical composition of angiogenesis inhibitors comprising aescin separated from the inventive Horse chestnut extract.

It is another object of the present invention to provide a pharmaceutical  
25 composition of angiogenesis inhibitors comprising esculetin or esculin separated from the inventive Horse chestnut extract.

It is another object of the present invention to provide a pharmaceutical



composition of angiogenesis inhibitors comprising quercitrin separated from the inventive Horse chestnut extract.

It is still another object of the present invention to provide a method of treating angiogenesis-dependent such as cancer metastasis, angioma, angiofibroma, diabetic retinopathy, premature infants retinopathy, neovascular glaucoma, corneal disease induced by angiogenesis, involutinal macula, macular degeneration, pterygium, retinal degeneration, retrolental fibroplasias, granular conjunctivitis, psoriasis, telangiectasis, pyogenic granuloma, seborrheic dermatitis, acne and arthritis with an effective amount of pharmaceutical composition according to the present invention.

It is still another object of the present invention to provide a method of treating MMP-dependent diseases such as atherosclerosis, restenosis, MMP-dependent osteopathy, inflammation of central nervous system, Alzheimer's disease, skin aging, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal ulcer synechia, bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss, myelinated nerve loss, liver fibrosis, nephroglomerular disease, germinal membrane rupture, inflammatory bowel disease, gingivitis, periodontitis, senile macular degeneration, diabetic retinopathy, proliferate vitreous body retinopathy, immature retinopathy, eye inflammation, conical cornea, Sjogren's syndrome, myopia eye tumor, rejection of cornea implantation, angiogenesis, infiltration and cancer metastasis, with an effective amount of pharmaceutical composition according to the present invention.

It is another object of the present invention to provide a toothpaste composition comprising Horse chestnut extract for prevention and treatment of MMP-dependent disease.

It is another object of the present invention to provide a use of the Horse chestnut extract for preparation of toothpaste composition for prevention and treatment of MMP-dependent disease.

It is another object of the present invention to provide a cosmetic composition for preventing skin aging comprising Horse chestnut extract having MMP-inhibitory activity or anti-angiogenesis activity.

It is another object of the present invention to provide a use of the Horse chestnut extract for preparation of cosmetic composition .

Hereinafter, the present invention will be explained in detail.

Horse chestnut of the present invention comprise Japanese Horse chestnut (*Aesculus turbinata* Blume), Chinese (*Aesculus chinensis* Bge and *Aesculus wilculus* Rehd) and European (*Aesculus hippocastanum* L.) and the inventive extract is extracted from the leaves or the seeds from Japanese, Chinese or European Horse chestnut.

Horse chestnut extract of the present invention can be purchased or prepared with conventional methods. Commercially available Horse chestnut extract can also be used.

An inventive extract may be prepared in accordance with the following preferred embodiment.

For the present invention, Horse chestnut leaves are dried at room temperature and cut into small pieces. Quick dried-seeds at 30-40°C or non-dried seeds are used and mashed or pulverized. The each powder is mixed with 3 to 10-fold, preferably, 5 to 7-fold volume of water, alcohols such as methanol, ethanol, butanol and the like, or the mixtures thereof, preferably, the mixture of water and methanol, more preferably 80% methanol; and is heated at a temperature ranging from 30 to 100°C, preferably from 50 to 80°C, for a period ranging from 1 to 48 hours, preferably 3 to 10 hours, with 3 to 10 times, preferably 7 times, by sonication, reflux or conventional extraction to obtain an aqueous crude extract. The crude extract is centrifuged, filtered and then lyophilized to obtain an extract powder. The powder is stored at 4°C until use.

In accordance with an aspect of the present invention, there is also provided a

anti-angiogenic composition comprising Horse chestnut extract for inhibiting angiogenesis.

In accordance with another aspect of the present invention, there is also provided a pharmaceutical composition comprising Horse chestnut extract as an active  
5 ingredient for prevention and treatment of various diseases associated with angiogenesis.

Horse chestnut extract of the present invention inhibited angiogenesis not only in tube formation assay, but also in mouse Matrigel model when it was orally administered.

The tube formation assay is an *in vitro* experimental method that is closely  
10 related to *in vivo* efficacy, and this method investigates the microvascular network of the human endothelial cell. *In vivo* angiogenesis can be quantitatively measured in mouse Matrigel assay.

The extract of Horse chestnut inhibits MMP, a family of essential enzymes for angiogenesis and cancer metastasis. When the effect of Horse chestnut extract on MMPs  
15 was investigated with MMP-2 and MMP-13, it drastically inhibited activities of both enzymes. The inhibitory effect of Horse chestnut extract on MMPs is not, however, limited to these enzymes.

It is therefore clear that Horse chestnut extract of the present invention is available as a drug for angiogenesis- and/or MMP-dependent diseases since it inhibits  
20 angiogenesis and MMPs.

As mentioned above, Horse chestnut extract of the present invention has inhibitory effects on angiogenesis and MMP activity. While MMPs are enzymes responsible for angiogenesis, anti-angiogenic activity of Horse chestnut extract is not limited to MMP inhibition activity of the Horse chestnut. That is, MMPs are one of  
25 the factors for inducing angiogenesis, and Horse chestnut extract can inhibit other factors of angiogenesis. Furthermore, MMP inhibitory activity of Horse chestnut are not limited to inhibition of angiogenesis.

In accordance with another aspect of the present invention, there is also provided a composition comprising Horse chestnut extract having MMP-inhibitory activity.

In accordance with another aspect of the present invention, there is also  
5 provided a pharmaceutical composition comprising Horse chestnut extract as an active ingredient for prevention and treatment of various MMP-dependent diseases.

The inventive pharmaceutical composition can be used to prevent and treat angiogenesis- and/or MMP-dependent diseases, such as atherosclerosis, restenosis, MMP-dependent osteopathy, inflammation of central nervous system, Alzheimer's  
10 disease, skin aging, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal ulcer synechia, bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss, myelinated nerve loss, liver fibrosis, nephroglomerular disease, germinal membrane rupture, inflammatory bowel disease, gingivitis, periodontitis, senile macular degeneration, diabetic retinopathy, proliferate vitreous body retinopathy,  
15 immature retinopathy, eye inflammation, conical cornea, Sjogren's syndrome, myopia eye tumor, rejection of cornea implantation, angiogenesis, infiltration and cancer metastasis and so on.

The composition of this invention may be used by itself or included with more than one of other angiogenesis inhibitors, such as ticlopidine, glucosamine (2-amino-2-  
20 deoxy-D-glucopyranose) and *Ginkgo biloba* extract for the prevention and/or treatment of angiogenesis- and MMP-dependent diseases. We have previously reported that angiogenesis is inhibited by commercially available pharmaceutical composition comprising various extract and compounds such as Melissa leaf extract (KR10-2000-75488), glucosamine or its salt (KR-10-2001-18675), *Ginkgo biloba* extract (KR10-  
25 2000-45265) and ticlopidine (KR10-2000-43589).

The composition of the present invention comprising Horse chestnut extract may also comprise more than one component of other anti-cancer, anti-inflammatory and

anti-aging agents such as *Glycyrrhiza glabra*, *Cinnamomum cassia*, *Sophora japonica*, *Atractylodes japonica*, *Atractylodes lancea*, *Artemisia capillaris*, *Morus alba*, *Houttuynia cordata*, *Lonicera japonica*, *Inula japonica*, *Inula britannica*, *Paeonia albiflora*, *Paeonia japonica*, *Paeonia obovata*, *Curcuma domestica*, *Curcuma longa*,  
5 *Saururus chinensis*, *Vaccinium myrtillus*, *Rubus spp.*, *Melilotus officinalis*, *Angelica gigantis*, *Salvia officinalis*, *Salvia miltiorrhiza*, *Liriope platyphylla*, *Zingiber officinalis*, *Ulmus davidiana*, *Ulmus macrocarpa*, *Camellia japonica* and *Vitis vinifera*. Above compositions can be added to drugs, quasi-drugs, foods or beverages used for anti-angiogenic purpose.

10 The anti-angiogenic activity of above component is also confirmed by tube formation of HUVEC as previously mentioned.

The combined composition of horse chestnut with other anti-angiogenic agents could contain about 5-95 w/w%, most preferably 25-75 w/w% of horse chestnut of this invention out of total active ingredients.

15 Inventive pharmaceutical composition can be comprised in pharmaceutically acceptable diluent such as saline, buffered saline, dextrose, water, glycerol, ethanol and the mixture thereof, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing co, Easton PA).

Accordingly, the present invention also provides a pharmaceutical composition  
20 for prevention and treatment of diseases caused by abnormal angiogenesis, which comprises the extract of Horse chestnut extract as an active ingredient, in combination with pharmaceutically acceptable excipients, carriers or diluents.

Examples of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, mannitol, starches, gum acacia, alginates, gelatin, calcium phosphate,  
25 calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoates, propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations may additionally include

fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known  
5 in the art.

A formulation may be prepared by using the composition in accordance with any of the conventional procedures. In preparing the formulation, the active ingredient is preferably admixed or diluted with a carrier or enclosed within a carrier, which may be in the form of a capsule, sachet or other container. When the carrier serves as a  
10 diluent, it may be a solid, semi-solid or liquid material acting as a vehicle, excipient or medium for the active ingredient.

Pharmaceutical formulations containing Horse chestnut extract may be prepared in any form, such as oral dosage form (tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment,  
15 lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).

The unit dosage of the formulation prepared above should contain 1 mg to 1000 mg, or preferably 5 to 500 mg of Horse chestnut extract in oral and injectable dosage forms. In general, 0.05 to 200 mg/kg of Horse chestnut extract can be administrated in  
20 a single dose or 2-3 divided doses per day. For a topical application, 0.1 to 10 % of horse chestnut extract should be included in the preparations such as emulsion, ointment, spray and toothpaste.

The pharmaceutical formulations comprising Horse chestnut extract of the present invention can be administered via various routes including oral, transdermal,  
25 subcutaneous, intravenous, intraperitoneal, intramuscular, intra-arterial, rectal, nasal, ocular, and topical introduction.

Horse chestnut extract composition may be applied differently according to the

purpose of dosing and diseases. It should be understood that the amount of active ingredient has to be determined with various factors. These factors include the severity of the patient's symptoms, other co-administrated drugs (e.g., chemotherapeutic agents), age, sex, body weight of the individual patient, food, dosing time, the chosen route of administration, and the ratio of the composition.

In accordance with another aspect of the present invention, there is also provided a toothpaste composition comprising Horse chestnut having MMP-inhibitory activity for prevention and treatment of MMP-dependent diseases such as gingivitis and periodontitis.

The toothpaste composition contains an abrasive cleaning agent, a humectant, a binder and a flavoring agent and Horse chestnut extract.

It is preferable that the present toothpaste composition contains 0.1-10% by the weight of the Horse chestnut extract based on the total weight of the composition. The other components may be a mixture of the gradients of an conventional toothpaste composition.

For example, a humectant is at least one or two substance selected from the group consisting of glycerine, sorbitol solution and amorphous sorbitol solution. An abrasive cleaning agent is calcium hydrogen phosphate, calcium carbonate, aluminum oxide, and the like. Additives used in a small content are ordinary components used in the tooth paste and include sweetening agents, pH controlling agents, antiseptic substance, coloring agents and binders.

The sweetening agents are sodium saccharide, aspartame and the like, the pH controlling agents are sodium phosphate, disodium phosphate, citric acid and the like., and the antiseptic substances are paraoxy benzoin methyl, sodium benzoin and the like.

The binders or thickeners are sodium carboxymethyl cellulose, carrageenan, xantan gum, etc. A foaming agent may be anionic and non-ionic surfactants of sodium lauryl sulfate, saccharose carboxylic ester and sorbitan carboxylic ester in a sole form or

in a combination of at least two thereof.

A flavoring agent is a mixture of peppermint oil, spearmint oil, menthol, etc., and other additives are enzyme such as dextranase, etc.

And the present invention to provide a use of the Horse chestnut extract for  
5 preparation of toothpaste composition to prevent and treat MMP-dependent diseases such as gingivitis and periodontitis.

In accordance with another aspect of the present invention, there is also provided a cosmetic composition for skin firmness comprising Horse chestnut having MMP-inhibitory activity.

10 It is preferable that the present cosmetic composition contains 0.1-10% by the weight of the Horse chestnut extract based on the total weight of the composition. The other components may be a mixture of the gradients of a conventional cosmetic composition known in the art.

Cosmetic formulations containing Horse chestnut extract may be prepared in any  
15 form such as cream, lotion, skin, gel, balm, spray solution and the like.

Furthermore, the present invention provides a use of the Horse chestnut extract for preparation of cosmetic composition for preventing skin aging.

Therefore, the above dose should not be intended to further illustrate the present invention without limiting its scope.

20

#### BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and features of the present invention will become  
25 apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, in which:



Figure 1 is a picture showing tube formation of human umbilical vein endothelial cells (HUVEC) as a control;

Figure 2 is a picture showing HUVEC treated with 100  $\mu\text{g}/\text{mL}$  of European Horse chestnut extract;

5        Figure 3 is a picture showing HUVEC treated with 10  $\mu\text{g}/\text{mL}$  of Horse chestnut extract;

Figure 4 is a picture showing HUVEC treated with 100  $\mu\text{g}/\text{mL}$  of Japanese Horse chestnut extract;

Figure 5 is a picture showing HUVEC treated with DMSO;

10       Figure 6 is a picture showing HUVEC treated with 50  $\mu\text{M}$  of esculin;

Figure 7 is a picture showing HUVEC treated with 50  $\mu\text{M}$  of esculetin;

Figure 8 is a picture showing HUVEC treated with 50  $\mu\text{M}$  of quercitrin;

Figure 9 is a picture showing HUVEC treated with 50  $\mu\text{M}$  of aescin;

15       Figure 10 is a graph showing the inhibition of angiogenesis by oral administration of Horse chestnut extract in the mouse Matrigel model;

Figure 11 is a graph showing inhibition of MMP-2 activity by Horse chestnut extract;

Figure 12 is a graph showing inhibition of MMP-13 activity by Horse chestnut extract.

20

### BEST MODE FOR CARRING OUT THE INVENTION

The following examples are intended to further illustrate the present invention.

25       However, these examples are shown only for better understanding the present invention without limiting its scope.

Example 1 : Preparation of extract from Horse chestnut leaf and seed

Dried Horse chestnut leaves (500g) or seeds (200g) were crushed by blender and soaked in 2L of 80% methanol. The solution was kept at 50°C for 12 hrs and further extracted by sonication. The filtrate was concentrated by vacuum evaporator.  
5 Finally, 120g of the extract from leaves and 53g of the extract from seeds were obtained and used in the following examples.

Example 2 : Identification of the constituents of the Horse chestnut extract

Crude extract of Horse chestnut of the above EXAMPLE 1 was suspended in  
10 distilled water and extracted with 1L of ethylacetate. After drying and solubilization in ethanol, an aliquot of the extract was subjected to paper chromatography (BuOH:HAc:H<sub>2</sub>O=4:1:5 vs. 2% ethylacetate)

From R<sub>f</sub> values with the standard compounds, the four main spots of the extract were identified as aescin, quercitrin, esculin and esculetin, respectively.

15

Experimental Example 1 : Effect of Horse chestnut extract on tube formation of HUVEC

The effect of Horse chestnut extract on angiogenesis was investigated *in vitro*  
20 with human endothelial cells.

In order to do the tube formation assay, blood vessel endothelial cells, human umbilical vein endothelial cells (HUVECs), were isolated from freshly obtained cords after cesarean section according to Grant's method (Grants DS, *et al.*, *Cell*, 58, pp933-943, 1989). They were identified by immunocytochemical staining with anti-Factor  
25 VIII antibody. HUVECs grown with Matrigel (BD Bioscience, Bedford, MA, USA), were treated with the above Horse chestnut extract of the Example 1, and further incubated at 37°C for 8-16 hrs. As a control, above procedure was repeated without

Horse chestnut extract.

Figure 1 shows that a tubular network is formed as a process of neovascularization, when they are grown on Matrigel.

Figures 2, 3 and 4 are pictures showing that the HUVECs grown on Matrigel treated with Horse chestnut extract cannot generate the microvascular network.

In order to identify the component responsible for anti-angiogenic activity of Horse chestnut extract, components identified as in EXAMPLE 2, were subjected to the tube formation assay as described above. Since those chemicals are not soluble in water, they were dissolved in dimethyl sulfoxide (DMSO). In order to exclude the effect of solvent, HUVECs treated with the same amount of DMSO were used as a control. Fig. 5 is a picture of the 1% DMSO-treated HUVEC control, and Figs. 6-9 are pictures showing the effect of individual components of the Horse chestnut on tube formation. At 50  $\mu$ M concentration, aescin completely inhibited the formation of microvascular network of HUVEC. Tubular network was disconnected by treatment with 50  $\mu$ M of quercitrin, and esculetin. The extent of inhibition of tube formation by esculin was less than that by esculetin, aglycon of the esculin.

The area of the tube was determined by image analysis program Image-Pro Plus<sup>®</sup> (Media Cybernetics, USA), and the results were summarized in Tables 1 and 2. As shown in Table 1, Horse chestnut extract inhibited HUVEC tube formation in a dose-dependent manner.

[Table 1]

Sample	Tube area	Percent inhibition
Control	10.55	0
Horse chestnut extract (100 $\mu$ g/ml)	0	100
Horse chestnut extract (10 $\mu$ g/ml)	8.89	16

[Table 2]

Sample	Area of the Tube (%)	Percent inhibition
Control	100	0
Esculin	85	15
Esculetin	17	83
Quercitrin	36	64
Aescin	0	100

5

Experimental Example 2 : Animal experiment for angiogenesis (mouse Matrigel model)

The anti-angiogenic activity of Horse chestnut extract was quantitatively measured in mouse Matrigel model.

0.4 ml portion of Matrigel mixed with 50 ng/ml of basic fibroblast growth factor (bFGF) and 50 units/ml of heparin was implanted into C57BL/6 female mice of 6 to 8 week old (Daehan Biolink Co., Ltd., Korea) by subcutaneous injection. To each mouse, 1.0 mg of Horse chestnut extract of the Example 1 was orally administered twice a day for four days. After five days, the Matrigel was recovered from excised skin of each mouse and the amount of hemoglobin(Hb) in the Matrigel was measured by Drabkin kit(Sigma Chemical Co., St. Louise, MI, USA, Cat. No. 525), a reagent for determination of total hemoglobin in blood.

As shown in Fig. 10 and Table 3, the average of total hemoglobin levels in the Matrigel from Horse chestnut extract-treated group were about 9.8% of that of the control group. That is, Horse chestnut extract potently inhibited growth factor induced angiogenesis by about 90% when it was administered orally.

[Table 3]

	Hemoglobin (g/dL)
Control	635 $\pm$ 50
Horse chestnut extract	62 $\pm$ 43

5

Experimental Example 3 : Effect of other anti-angiogenic extract on tube formation of HUVEC

The anti-angiogenic activity of *Atractylodes japonica* extract, *Artemisia*  
 10 *capillaris* extract, *Vaccinium myrtillus* extract, *Houttuynia cordata* extract, and *Paeonia*  
*japonica* extract were also confirmed by tube formation of HUVEC experiment  
 prosecuted by the procedure according to above Experimental Example 1. The inhibition  
 of tube formation by 50  $\mu\text{g}/\text{ml}$  of each composition was 30-60% as compared with non-  
 treated control HUVEC. Percent inhibition by 50  $\mu\text{g}/\text{ml}$  of crude extract show 52% for  
 15 *Atractylodes japonica*, 53% for *Artemisia capillaris*, 40% for *Vaccinium myrtillus*, 30%  
 for *Houttuynia cordata*, and 38% for *Paeonia japonica*.

(Table 4)

	Percent tube area	Percent inhibition
Control	100	0
<i>Atractylodes japonica</i>	48	52
<i>Artemisia capillaris</i>	47	53
<i>Houttuynia cordata</i>	70	30
<i>Vaccinium myrtillus</i>	60	40
<i>Paeonia japonica</i>	62	38

Experimental Example 4 : Effect of Horse chestnut extract on Matrix Metalloproteinase activity

5 (1) Preparation of MMP

MMP-2 and MMP-13 were cloned and prepared from insect cells (Sf21 insect cell) by using a Baculovirus system.

MMP-2 cDNA (GENBANK No. XM\_048244) was cloned to a pBlueBac4.5 transfer vector (Invitrogen, Cat No. V1995-20), and then transfected to Sf9 cells with  
10 a Bac-N-Blue Transfection Kit (Invitrogen, Cat No. K855-01). Sf21 cells were incubated with a TNM-FH (Sigma Co, St. Louis, MO, U.S.A) media containing 10% fetal bovine serum at 27 °C, then harvested and re-suspended at a concentration of  $10^7$  cell/ml. The cell suspension was incubated with a virus containing the cloned gene for 1 hr at room temperature. Infected Sf21 cells were grown for 72 hrs and the medium  
15 was recovered, and the MMP-2 was purified with a gelatin-sepharose affinity column from the recovered medium.

MMP-13 (GENBANK NO. XM\_002427) was prepared from the corresponding genes as previously described, and purified with SP-sepharose chromatography.

20

(2) Inhibition of MMP activity

In order to investigate MMP inhibition by Horse chestnut extract, MMP enzyme activity was assayed by a spectrofluorometric method (Perkin-Elmer LS50B).

Purified MMP-2 and MMP-13 were used after activation with 1 mM APMA  
25 before assay.

The substrate for MMP-2 was MCA-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH<sub>2</sub> (BACHEM, Cat. No. M-1895), and MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH<sub>2</sub>

was used as a substrate for MMP-13.

As a control, 10 nM MMP-2 and 10  $\mu$ M MMP-2 substrate were mixed in 2 ml of reaction buffer (50 mM Tricine (pH 7.5), 10 mM  $\text{CaCl}_2$ , 200 mM NaCl) in a 2 ml cuvette. Fluorescence intensity was measured for 5-10 min at room temperature with a spectrofluorometer under an excitation wavelength of 325 nm and an emission wavelength of 393 nm.

Horse chestnut extract (25  $\mu\text{g}/\text{ml}$ ) dissolved in water and 10 nM MMP-2 were added to a reaction buffer containing a substrate, and fluorescence intensity was measured in the same manner.

Activity for MMP-13 was also assayed, and fluorescence intensity was measured as previously mentioned.

Figures 11 and 12 are diagrams of activity of MMP-2, and MMP-13. The inhibition of MMP-2 and MMP-13 by Horse chestnut extract was 77% (Fig. 11) and 85% (Fig. 12), respectively.

As mentioned previously, Horse chestnut extract of the present invention inhibits angiogenesis and matrix metalloproteinase activity. Based on such results, Horse chestnut extract can be used for prevention and treatment of angiogenesis and/or MMP-dependent diseases.

#### Preparation Example 1 : Preparation of syrup

In this invention, syrup containing 2% Horse chestnut extract can be prepared as follows;

Dried powder of Horse chestnut extract, saccharin, glucose was dissolved in 80g of warm water. After cooling, other ingredients were added thereto a volume of 100 ml.

Dried powder of Horse chestnut extract	2.0 g
Saccharin	0.8 g

	Glucose	25.4 g
	Glycerin	8.0 g
	Fragrant	0.04 g
	Ethanol	4.0 g
5	Sorbic acid	0.4 g
	Distilled water	q.s.

Preparation Example 2 : Preparation of tablet

- 10 A tablet containing Horse chestnut extract was prepared with the following ingredients by mixing dried powder of Horse chestnut extract with lactose, starch and silica. Solution of 10% gelatin was added thereto, and the mixture was granulated by passing through the 14 mesh pharmaceutical sieve. After drying, granules were mixed with remaining ingredients and tableting was performed.

15	Dried powder of Horse chestnut extract	25.0 g
	Lactose	17.5 g
	Starch	34.0 g
	Colloidal silica	3.2 g
	Talc	5.0 g
20	Magnesium Stearate	0.5 g
	10% gelatin	10 ml

Preparation Example 3 : Preparation of injectable solution

- 25 Horse chestnut extract, sodium chloride and ascorbic acid were dissolved in distilled water. When it dissolved completely, adequate amount of water was added thereto, to make the solution 100 ml. The solution was sterilized as conventional method.



23

Dried powder of Horse chestnut extract	1.0 g
Sodium chloride	0.6 g
Ascorbic acid	0.1 g
Distilled water	q.s.

5

Preparation Example 4 : Preparation of ointment

Horse chestnut extract, diethyl sebacate, polyoxyethylene and sodium benzoic acid were mixed in vaseline completely. And then adequate amount of Vaseline was added thereto, to make the mixture 100g.

10	Dried powder of Horse chestnut extract	5.0 g
	Diethyl sebacate	8g
	Polyoxyethylene	6g
	Sodium benzoic acid	q.s
	Vaseline	q.s.

15

Preparation Example 5 : Preparation of toothpaste

Horse chestnut extract with the component listed in below were mixed in water completely. And then adequate amount of water was added thereto, to make the mixture 100g.

20	Dried powder of Horse chestnut extract	5.0 g
	Calcium Hydrogen Phosphate	40g
	Amorphous Sorbitol	25g
	Sodium Alkyl Sulfate	2g
	Sodium Saccharide	0.1g
25	Carboxyl Methyl Cellulose	1g
	Peppermint Oil	0.8g
	Water	q.s.

Preparation Example 6 : Preparation of lotion

Horse chestnut extract with the component listed in below were mixed in water completely. And then adequate amount of water was added thereto, to make the mixture 100g.

5	Dried powder of Horse chestnut extract	5.0 g
	L-ascorbic acid-2-magnesium phosphate	1.0g
	Collagen	1.0g
	Citric acid	0.05g
10	Sodium citrate	0.1g
	1,3-butyl glycerol	3.0g
	Water	q.s.

15 INDUSTRIAL APPLICABILITY

As above mentioned, Horse chestnut extract of the present invention inhibits angiogenesis and matrix metalloproteinase activity.

Based on the results, Horse chestnut extract can be used as a new composition for prevention and treatment of angiogenesis- and/or MMP-dependent diseases.

CLAIMS

1. A composition comprising a Horse chestnut extract for inhibiting angiogenesis.
- 5 2. A pharmaceutical composition comprising a Horse chestnut extract of claim 1 for prevention and treatment of angiogenesis - dependent diseases.
3. A composition comprising a Horse chestnut extract for inhibiting matrix  
10 metalloproteinase activity.
4. A pharmaceutical composition comprising a Horse chestnut extract of claim 3 for prevention and treatment of matrix metalloproteinase – dependent diseases.
- 15 5. The composition of any claims 1 to 4, wherein said extract is made from *Aesculus turbinata* Blume, *Aesculus chinensis* Bge or *Aesculus wilculus* Rehd *Aesculus hippocastanum* L.
6. The composition of claim 5, wherein said extract is made from leaves or  
20 seeds of *Aesculus turbinata* Blume, *Aesculus chinensis* Bge or *Aesculus wilculus* Rehd *Aesculus hippocastanum* L.
7. The composition according to claim 1 or 2, wherein the composition is used for treatment of a disease selected from the group consisting of cancer metastasis,  
25 angioma, angiofibroma, diabetic retinopathy, premature infant's retinopathy, neovascular glaucoma, corneal disease induced by angiogenesis, involutional macula, macular degeneration, pterygium, retinal degeneration, retrolental fibroplasias,

granular conjunctivitis, psoriasis, telangiectasis, pyogenic granuloma, seborrheic dermatitis, acne, and arthritis.

8. The pharmaceutical composition of claim 3 or 4, wherein said  
5 pharmaceutical composition is used for prevention and treatment at least one of  
disease selected from the group consisting of atherosclerosis, restenosis, MMP-  
dependent osteopathy, inflammation of central nervous system, Alzheimer's disease,  
skin aging, rheumatoid arthritis, osteoarthritis, septic arthritis, corneal ulcer synechia,  
bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss,  
10 myelinated nerve loss, liver fibrosis, nephroglomerular disease, germinal membrane  
rupture, inflammatory bowel disease, gingivitis, periodontitis, senile macular  
degeneration, diabetic retinopathy, proliferate vitreous body retinopathy, immature  
retinopathy, eye inflammation, conical cornea, Sjogren's syndrome, myopia eye tumor,  
rejection of cornea implantation, angiogenesis, infiltration and cancer metastasis.

15

9. The pharmaceutical composition of claim 2 or 4, wherein said  
pharmaceutical composition is provided in an acceptable carrier as tablet, capsule, soft  
capsule, aqueous medicine, syrup, elixirs, pill, powder, sachet, granule or injectable  
solution.

20

10. The pharmaceutical composition of claim 2 or 4, wherein said  
pharmaceutical composition is provided in an acceptable carrier as a topical cream,  
lotion, ointment, gel, balm, spray or paste.

25

11. Use of the Horse chestnut extract for preparation of pharmaceutical  
composition to inhibit and treat angiogenesis-dependent diseases.

12. Use of the Horse chestnut extract for preparation of pharmaceutical composition to inhibit MMP activity.

13. A pharmaceutical composition comprising aescin separated from the inventive Horse chestnut extract for inhibiting angiogenesis.

14. A pharmaceutical composition comprising esculetin or esculin separated from the inventive Horse chestnut extract for inhibiting angiogenesis.

15. A pharmaceutical composition comprising quercitrin separated from the inventive Horse chestnut extract for inhibiting angiogenesis.

16. A toothpaste composition comprising Horse chestnut extract of claim 1 or 3 for prevention and treatment of MMP-dependent diseases.


17. Use of the Horse chestnut extract for preparation of toothpaste composition to prevent and treat MMP-dependent diseases.

18. A cosmetic composition comprising Horse chestnut extract of claim 1 or 3 for skin firmness having anti-angiogenesis activity and MMP-inhibitory activity.

19. Use of the Horse chestnut extract for preparation of cosmetic composition for preventing skin aging.


1/12

Fig. 1




2/12

Fig. 2



3/12


Fig. 3






4/12

Fig. 4




5/12

Fig. 5



6/12

Fig. 6




7/12

Fig. 7




8/12

Fig. 8




9/12

Fig. 9




10/12

Fig. 10



11/12


Fig. 11





12/12

Fig. 12



**A. CLASSIFICATION OF SUBJECT MATTER**

IPC7 A61K 35/78, A61K 47/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K 35/78, A61K 47/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PUBMED ON LINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5080901 A (HANGAY ET AL), 14 JAN. 1992 SEE ABSTRACT & COLUMNS 1-4	1, 2, 5, 6, 7, 9, 10, 11, 13-15, 19
A	EP 0900563 A1 (KLINGE PHARMA GMBH), 10 MAR. 1999 SEE ABSTRACT & PAGES 1-5	1, 2, 5, 6, 7, 9, 10, 11, 13
A	JP 62-81325 (MARUZEN KASEI KK), 14 APR. 1987 SEE PAGES 1-3	1, 2, 4
A	US 4663354 A (NEIDERHAUSER ET AL), 5 MAY 1987 SEE TABLE 5 & COLUMNS 5, 6	1, 2, 7
A	LOEW D. ET AL 'MEASUREMENT OF THE BIOAVAILABILITY OF AESCIN- CONTAINING EXTRACTS.' IN; METHODS. FIND EXP. CLIN. PHARMACOL 2000 SEP. ;22(7);537-542	1, 2, 13.
A	MATSUDA H ET AL. 'EFFECTS OF ESCINS Ia, Ib, IIa, AND IIb FROM HORSE CHESTNUT, THE SEEDS OF AESCULUS HIPPOCASTANUM L., ON ACUTE INFLAMMATION IN ANIMALS.' IN; BIOL.PHARM. BULL. 1997 OCT.;20(10);1092-1095	1, 2, 7, 13

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

28 FEBRUARY 2003 (28.02.2003)

Date of mailing of the international search report

28 FEBRUARY 2003 (28.02.2003)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office  
920 Dunsan-dong, Seo-gu, Daejeon 302-701,  
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

CHO, Hee Won

Telephone No. 82-42-481-5607



Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5080901 A	14/01/1992	JP 2117619 A2 HU 0202743 B FI 0893094 A0	02/05/1990 29/04/1991 22/07/1989
EP 0900563 A1	10/03/1999	US 6077534 A CA 2245370 AA	20/07/2000 02/03/1999
JP 62-81325 A	14/04/1987	NONE	
US 4663354 A	05/05/1987	NONE	